Skip to content Skip to footer

Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

Langgan

Surat Berita

订阅我们的月讯

Subscribe to our

Newsletter